
ABVC BioPharma fell 68.8% from $2.92 to $0.91, behind the S&P 500's +10.6%. Its worst day was Jul 9 (−28.2%), and its low came Aug 26 at $0.71.
Nov 18, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
ABVC BioPharma shares fell 15.8%, while the S&P 500 fell 1.2%.
−15.8% · S&P 500 −1.2%
EPS of $-0.16 was reported on $0.00 revenue.
+2.1% · S&P 500 +0.7%
Story events cover the past 12 months · Times ET
ABVC BioPharma shares rose 27.5%, while the S&P 500 rose 0.5%.
+27.5%, the year's best day · S&P 500 +0.5%
EPS of $-0.06 was reported on $0.00 revenue.
−1.8% · S&P 500 −0.1%
ABVC BioPharma shares fell 28.2%, while the S&P 500 rose 0.8%.
−28.2%, the year's worst day · S&P 500 +0.8%
EPS of $-0.03 was reported on $0.00 revenue.
−0.1% · S&P 500 +0.7%
ABVC BioPharma closed at its lowest level of the year, 75.7% below where the year started.
−11.1% · S&P 500 0.0%
ABVC BioPharma shares rose 15.7%, while the S&P 500 rose 1.0%.
+15.7% · S&P 500 +1.0%
EPS of $0.04 was reported on $0.00 revenue.
0.0% · S&P 500 +1.3%
Where it ended: a close of $0.91 on Nov 18, 2026. Up next: Q4 2026 earnings on Mar 2, 2027.
Nothing in the past 12 months.
All ABVC analyst actionsNothing in the past 12 months.
All ABVC dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ABVC and SPY from Benzinga historical bars. Not investment advice.